^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
SureSeq™ CLL + CNV Panel

Company:
Sysmex Corp
Type:
Laboratory Developed Test
Related tests:
Evidence

News

3ms
GENETIC PREDICTORS OF PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHTS FROM NEXT-GENERATION SEQUENCING (EBMT 2024)
Our analysis revealed that specific genetic mutations and chromosomal alterations are strongly associated with the disease's course and patient prognosis. Particularly, the presence of unmutated IGHV and TP53 mutations emerged as key indicators of a more aggressive disease course and shorter treatment-free intervals. These findings underscore the critical role of advanced genetic testing in identifying patients who may require more intensive treatment and monitoring.
IO biomarker • Next-generation sequencing
|
IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
|
TP53 mutation • Chr del(17p) • Chr del(11q) • Chr del(17p) + Chr del(11q) • TS 12
|
LymphoTrack® Dx IGH Assay • SureSeq™ CLL + CNV Panel
3ms
OGT expands NGS operations to state-of-the-art facility in Oxford Technology Park (Sysmex Press Release)
"OGT...announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand. Equipped with cutting-edge technology, the facilities will drive development of OGT’s trusted SureSeq™ next generation sequencing (NGS) product portfolio, as well as deliver expert-led training and enhanced opportunities for collaboration."
Clinical
|
SureSeq™ CLL + CNV Panel • SureSeq™ Germline Breast Cancer + CNV Panel • SureSeq™ Myeloid MRD Panel • SureSeq™ Myeloid Plus Panel • SureSeq™ Pan-Myeloid Panel
6ms
OGT and Intelliseq launch NGS reporting and interpretation for all myeloid malignancy panels (Sysmex Press Release)
"OGT, A Sysmex Group Company...and Intelliseq...are delighted to announce the release of GeneSpect™ Somatic Reporter for use with OGT’s SureSeq™ portfolio of next generation sequencing (NGS) panels. This advanced analytical reporting solution pairs state-of-the-art variant interpretation and reporting with OGT’s class-leading NGS panels and bioinformatics solutions. Users of SureSeq Myeloid panels can now benefit from insightful tertiary reporting for all myeloid malignancy content and variants with the GeneSpect Somatic Reporter."
Launch
|
SureSeq™ CLL + CNV Panel • SureSeq™ Germline Breast Cancer + CNV Panel • SureSeq™ Myeloid Plus Panel • SureSeq™ Pan-Myeloid Panel